Business Description
Aktis Oncology is a Boston-based clinical-stage company focused on developing radioactive drug treatments that target and destroy solid tumor cancers. Its two lead candidates use a miniprotein platform to deliver a radioactive element directly to cancer cells expressing specific proteins, with one currently in Phase 1b trials across multiple cancer types including bladder, breast, and lung cancer. The company works with several research and industry partners, including Eli Lilly, to advance its pipeline.
